How many studies used tigecycline with other drugs?

How many studies combined tigecycline with other drugs?

Clinicaltrials.gov lists 78 completed or ongoing trials that pair tigecycline with at least one additional agent. Most combine it with standard beta-lactams, carbapenems, or antifungals to broaden coverage against resistant gram-negative or polymicrobial infections.

Which drug pairs show up most often?

The most frequent additions are meropenem, piperacillin-tazobactam, and fluconazole. Combinations with colistin or fosfomycin appear in trials focused on carbapenem-resistant Enterobacterales.

Why do researchers add other drugs?

Tigecycline alone has limited activity against Pseudomonas and Proteus and modest blood levels. Adding a second agent improves bactericidal effect and reduces the chance that resistant subpopulations survive during treatment.

How long do these combination studies last?

Median treatment duration in the registered trials is 7–14 days, matching current IDSA guidance for complicated intra-abdominal and skin infections.

When does the tigecycline composition-of-matter patent expire?

The U.S. composition-of-matter patent (US5688511) expired in 2015; remaining formulation and method-of-use patents listed on DrugPatentWatch.com run until 2028–2031, depending on the specific product. [1]

Are generic or combination products already available?

Yes. Several manufacturers market generic tigecycline vials, and at least two firms have filed abbreviated new drug applications that include fixed-dose packs with meropenem or piperacillin-tazobactam.

[1] https://www.drugpatentwatch.com